Nov 16, 2022 / 09:45AM GMT
Akash Tewari - Jefferies LLC, Research Division - Equity Analyst
Good day, everyone. Day 2 of our health care conference. For those who don't know me. My name is Akash Tewari. I am one of the therapeutic analysts here at Jefferies. I have the pleasure of hosting Andrew Peters, Senior Vice President and Head of Strategy at Exelixis. Andrew is very happy that he's not on this side anymore having started his own companies.
(technical difficulty)
for some brief introductory remarks, and then we'll get into some more specifics. Go ahead.
Andrew Ross Peters - Exelixis, Inc. - SVP of Strategy
Yes. Thanks for having me, and thanks for the invite. Just before I start, I'd like to say, likely going to be some -- making some forward-looking statements today. So please see our SEC filings for necessary risks to our business.
So Exelixis is a commercial-stage oncology company. Our lead product, cabozantinib, commercial name CABOMETYX, approved in RCC and a couple of other different tumor types, on market now giving guidance for 2022 revenue of $1
Exelixis Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers